Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Coherus Oncology, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.000 -- 00:00:04.740 a phone keypad. If you'd like to withdraw your question, press star one again. 00:00:04.740 -- 00:00:09.620 Thank you. I'd now like to turn the conference over to Jody Sievers, Head of Investor 00:00:09.620 -- 00:00:14.380 Relations for Coherence Oncology. You may begin. 00:00:14.880 -- 00:00:20.660 Thank you, Jordan. Good afternoon and welcome to Coherence Oncology second quarter, 2025 00:00:20.660 -- 00:00:26.540 earnings conference call. Joining me today to discuss our results are Denny Lanphier, 00:00:26.540 -- 00:00:32.100 Chief Executive Officer of Coherence, Brian McMichael, Chief Financial Officer, 00:00:32.100 -- 00:00:37.460 Dr. Rosh Diaz, Chief Medical Officer, Dr. Teresa Lavallee, Chief Scientific 00:00:37.460 -- 00:00:43.260 Officer, Chief Scientific and Development Officer, Mayor Goria Gauker, 00:00:43.260 -- 00:00:47.880 Executive Vice President, Commercial. Before we get started, I would like to remind you 00:00:47.880 -- 00:00:53.200 that today's call includes forward-looking statements regarding Coherence's current expectations 00:00:53.200 -- 00:00:58.340 about future events. Actual results may vary significantly and 00:00:58.340 -- 00:01:03.600 we undertake no duty to update or revise any forward-looking statement. 00:01:03.600 -- 00:01:09.060 Please see the press release that we issued today and our quarterly report on form 10Q 00:01:09.060 -- 00:01:12.240 for more information on risks and uncertainties. 00:01:12.240 -- 00:01:15.360 And now I'll turn the call over to Denny. 00:01:15.360 -- 00:01:20.700 Oh, thank you, Jody, and welcome all. In Q2, 2025, we completed our 00:01:20.700 -- 00:01:25.560 strategic repositioning and renamed our company Coherence Oncology to better reflect 00:01:25.560 -- 00:01:30.660 o...